Science & technology

A leader in immuno-oncology targeting innate immunity cells.

The Company specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. The mechanisms controlling these cells were described in the late 90’s notably by the teams of the scientists who founded Innate Pharma.

It is on the basis of this science that Innate Pharma develops drug candidates for cancer and in inflammation.

Many of the ligands for innate immunity receptors are expressed on cancer cells, opening the way for the Company to develop directly cytotoxic antibodies.